Literature DB >> 16998790

Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells.

Annalisa Capobianco1, Patrizia Rovere-Querini, Claudio Rugarli, Angelo A Manfredi.   

Abstract

Dendritic cells (DCs) and natural killer (NK) cells are key players at the interface between innate resistance and acquired immunity. NK cells can induce DC maturation, a differentiation process whereby DCs respond to a environmental stimulus and acquire the ability of eliciting adaptive immunity. Conversely, maturing DCs promote NK functions in vivo and in vitro. This interplay has important consequences on the immune response to pathogens and possibly to neoplastic cells. Here, we show that B16 melanoma cells actively modulate the interaction between DCs derived from bone marrow precursors and NK/LAK cells propagated from the spleen of C57BL/6 mice. DCs increased in a dose-dependent manner the ability of NK/LAK cells to kill melanoma cells and to produce cytokines. This activatory cross-talk entailed the production of IL-18 by DCs and of IFN-gamma by NK/LAK cells. Melanoma cells were not a passive target of NK activity; they regulated the outcome of the interaction between DCs and NK/LAK cells, inhibiting the in vitro production of cytokines as effectively as the genetic deletion of IL-18 or IFN-gamma. Interference with the NK/DC interaction possibly represents a mechanism used by growing tumors to evade the immune response. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998790     DOI: 10.1002/ijc.22279

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  CD200 is induced by ERK and is a potential therapeutic target in melanoma.

Authors:  Kimberly B Petermann; Gabriela I Rozenberg; Daniel Zedek; Pamela Groben; Karen McKinnon; Christin Buehler; William Y Kim; Janiel M Shields; Shannon Penland; James E Bear; Nancy E Thomas; Jonathan S Serody; Norman E Sharpless
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

2.  Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.

Authors:  E J West; K J Scott; V A Jennings; A A Melcher
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.